More Data Support Olaparib-Abiraterone in BRCA-Mutant Prostate Cancer
Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer significantly improved progression-free survival (PFS) versus either agent alone, according to findings from a small phase II trial presented at this year’s Genitourinary Cancers Symposium. In this exclusive MedPage Today video, Daniel Geynisman, MD, of Fox Chase […]